Hydrocortisone in Hypotensive Newborn

Neonatal Haemodynamics Vasoactive Pharmacology

When blood pressure won’t hold despite fluid and two inotropes, the problem may not be the heart or the vessels at all — it may be the adrenal gland. This is where hydrocortisone earns its place.

The bottom line

Hydrocortisone is a rescue agent, not a first move. In catecholamine-resistant hypotension — often underpinned by relative adrenal insufficiency — it reliably raises blood pressure and lets you wean the pressors. Its single most important safety rule: never give it alongside indomethacin.

<200

nmol/L — an unstimulated cortisol commonly taken to suggest adrenal insufficiency in an unstable newborn (thresholds vary)¹

90%

of surveyed Indian NICU physicians chose hydrocortisone as their corticosteroid for neonatal hypotension¹⁰

2 h

time within which hydrocortisone raised mean BP in a cooled-HIE RCT, cutting inotrope dose and duration⁸

01 Why an adrenal drug for a blood-pressure problem

Preterm infants, especially those of extremely low birth weight, frequently show relative adrenal insufficiency from an immature hypothalamic-pituitary-adrenal axis. Circulating cortisol falls with decreasing gestational age, and lower cortisol tracks with lower blood pressure and greater, longer inotrope requirements.¹

Under severe stress these infants cannot mount an adequate cortisol response. The consequence is downregulation of cardiovascular adrenergic receptors and pressor resistance — the picture of “vasopressor-resistant hypotension,” driven by a combination of transient adrenocortical insufficiency and adrenergic receptor downregulation.²

02 How hydrocortisone reverses it

Hydrocortisone has both glucocorticoid and mineralocorticoid activity, and re-sensitises the failing cardiovascular system to catecholamines through several linked mechanisms:^3,2

Restores receptor signalling

Upregulates adrenergic and angiotensin receptor expression on vascular smooth muscle and myocardium, reversing the desensitisation caused by prolonged catecholamine exposure.

Sensitises to catecholamines

Increases vascular and myocardial responsiveness to circulating catecholamines and slows their metabolic breakdown, prolonging their effect.

Damps down vasodilators

Reduces the activity of inflammatory vasodilatory mediators (such as inducible nitric oxide synthase), a major driver of vasodilatory shock.

Seals the leak

Improves endothelial integrity and reduces capillary leak in inflammatory states such as sepsis, helping preserve intravascular volume.

03 Where it actually belongs

Not a primary or prophylactic treatment — hydrocortisone is reserved for specific, severe states.

Refractory (catecholamine-resistant) hypotension

The core indication: still hypotensive despite high-dose dual inotropes. Low-dose hydrocortisone raises blood pressure and reduces vasopressor requirement without compromising cardiac function or cerebral and renal perfusion.^4,5,6

Post-PDA-ligation cardiac syndrome

After surgical PDA ligation, a subset of preterm infants develop catecholamine-resistant hypotension; low post-operative cortisol is strongly associated with that refractoriness, and these infants respond to hydrocortisone.⁷

Circulatory failure during cooling for HIE

In a randomised controlled trial of cooled, asphyxiated neonates with volume-resistant hypotension, low-dose hydrocortisone raised mean BP within 2 hours (94% vs 58% reached target) and significantly reduced the peak dose, cumulative dose and duration of inotrope support.⁸

04 Practice varies — and so does the threshold to start

Hydrocortisone is the near-universal corticosteroid choice, but when clinicians reach for it differs widely. In the Indian NICU survey, hydrocortisone was used by 90% of respondents, but timing ranged from second-line to fourth-line:¹⁰

55% — third-line

Started after two inotropes were already running — the commonest practice.

26% — fourth-line

Held back until after three inotropes.

6% — second-line

Introduced early, after a single inotrope.

10% — never

Did not use corticosteroids for hypotension at all.

A sensible screen. Unit guidelines typically restrict hydrocortisone to infants still hypotensive despite dual inotropes, especially those under 30 weeks’ gestation, under 14 days old, and under concurrent perinatal stress (severe RDS, mechanical ventilation, recent surgery) (unit guideline) — consistent with the recommendation to reserve it for genuinely vasopressor-resistant hypotension.⁶

05 Dosing, the one interaction that matters, and safety

Optimal dosing remains genuinely unresolved — regimens in the literature vary several-fold.³ Common schedules:

Representative hydrocortisone regimens

Common start

1–2 mg/kg (or 15 mg/m²) IV every 6–12 h; the interval is often lengthened in infants under 35 weeks⁹

Loading regimen

Some unit guidelines use 2.5 mg/kg (repeatable at 4 h), then 2.5 mg/kg every 6 h for 48 h or until BP recovers, tapering over ≥48 h (unit guideline)

Short courses

If treatment is ≤3 days, it can usually be stopped without a taper, as the HPA axis is not yet suppressed (expert consensus)

Never co-administer with indomethacin. Combined exposure to hydrocortisone and indomethacin (or other NSAIDs) in extremely preterm infants significantly increases the risk of spontaneous intestinal perforation — in a meta-analysis the risk rose (OR ~2.5) only when hydrocortisone was given with indomethacin, not with hydrocortisone alone.^9,6

Hydrocortisone, not dexamethasone. Dexamethasone is avoided for hypotension because of its association with adverse neurodevelopmental outcomes; hydrocortisone acts more like endogenous cortisol and appears safe short-term, with more reassuring neurodevelopmental data.³ Even so, high-quality long-term outcome and disability-free-survival data after early hydrocortisone remain limited.⁵

References

Ng PC, Lee CH, Lam CWK, et al. Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2004;89(2):F119–F126. doi.org/10.1136/adc.2002.021972
Biniwale M, Sardesai S, Seri I. Steroids and vasopressor-resistant hypotension in preterm infants. Curr Pediatr Rev. 2013;9(1):75–83. doi.org/10.2174/157339613805289505
Ramaswamy VV, Kumar G, Pullattayil AK, et al. Timing of hydrocortisone therapy in neonates with shock: a systematic review, meta-analysis and clinical practice guideline. Front Pediatr. 2025;13:1491976. doi.org/10.3389/fped.2025.1491976
Noori S, Friedlich P, Wong P, et al. Hemodynamic changes after low-dosage hydrocortisone administration in vasopressor-treated preterm and term neonates. Pediatrics. 2006;118(4):1456–1466. doi.org/10.1542/peds.2006-0661
Higgins S, Friedlich P, Seri I. Hydrocortisone for hypotension and vasopressor dependence in preterm neonates: a meta-analysis. J Perinatol. 2009;30(6):373–378. doi.org/10.1038/jp.2009.126
Seri I. Management of hypotension and low systemic blood flow in the very low birth weight neonate during the first postnatal week. J Perinatol. 2006;26(Suppl 1):S8–S13. doi.org/10.1038/sj.jp.7211464
Clyman RI, Wickremasinghe AC, Merritt TA, et al. Hypotension following patent ductus arteriosus ligation: the role of adrenal hormones. J Pediatr. 2014;164(6):1449–1455. doi.org/10.1016/j.jpeds.2014.01.058
Kovacs K, Szakmar E, Meder U, et al. A randomized controlled study of low-dose hydrocortisone versus placebo in dopamine-treated hypotensive neonates undergoing hypothermia for hypoxic-ischemic encephalopathy. J Pediatr. 2019;211:13–19.e3. doi.org/10.1016/j.jpeds.2019.04.008
Watterberg KL, Shaffer ML, Baud O, et al. Effect of prophylaxis for early adrenal insufficiency using low-dose hydrocortisone in very preterm infants: an individual patient data meta-analysis. J Pediatr. 2019;207:136–142.e5. doi.org/10.1016/j.jpeds.2018.10.004
Das R, Nagpal R, Deshpande S, et al. A survey on management practices of hypotension in preterm neonates: an Indian perspective. Front Pediatr. 2024;12:1411719. doi.org/10.3389/fped.2024.1411719

Tiny Taught · Neonatal & Paediatric Education

Educational summary for clinicians and trainees. Referenced to primary sources; items marked unit guideline or expert consensus reflect practice rather than trial evidence. Doses are for orientation only — always follow your unit’s formulary and senior review. This supports, and does not replace, local guidelines and individualised clinical judgement.